HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

maraviroc

Also Known As:

4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; Pfizer Brand of maraviroc; Selzentry; UK-427,857; UK-427857

Networked: 176 relevant articles (13 outcomes, 30 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 5
        Cyclohexanes: 2
        maraviroc: 176
Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Triazoles: 187
      - maraviroc: 176

Experts

1.	Heera, Jayvant: 9 articles (06/2015 - 01/2010)
2.	van der Ryst, Elna: 8 articles (06/2015 - 01/2005)
3.	Mayer, Howard: 7 articles (12/2010 - 10/2008)
4.	Westby, Mike: 7 articles (03/2010 - 01/2005)
5.	Goodrich, James: 6 articles (12/2010 - 10/2008)
6.	Clotet, Bonaventura: 5 articles (10/2015 - 10/2008)
7.	Fätkenheuer, Gerd: 5 articles (03/2015 - 10/2008)
8.	Nelson, Mark: 5 articles (01/2012 - 10/2008)
9.	Gulick, Roy M: 4 articles (10/2015 - 10/2008)
10.	Hoepelman, Andy I M: 4 articles (07/2015 - 10/2008)

Related Diseases

1.	Infection 01/01/2007 - "Maraviroc is only effective against CCR5-tropic virus, which predominates throughout infection but is more common in patients at the early asymptomatic stage of infection." 05/01/2010 - "Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection." 12/15/2010 - "Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2." 10/01/2014 - "In combination studies, R4.0, CCL5, and maraviroc exhibited concomitant interactions with CCR5 and promoted synergic inhibition of HIV-1 in acute-infection assays. " 02/01/2014 - "Maraviroc, a CCR5 antagonist blocking coreceptor binding during HIV entry, is active in vitro against CCR5-tropic HIV-2 but more studies are needed to validate its use in therapeutic treatments against HIV-2 infection. "
2.	HIV Infections (HIV Infection) 12/01/2015 - "We used bone marrow/liver/thymus (BLT) humanized mice to establish the effect of semen on vaginal HIV infection and on the efficacy of topically applied maraviroc. " 01/01/2012 - "This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. " 10/23/2015 - "Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers." 06/01/2015 - "The demonstration that individuals with a 32-bp deletion within the CCR5 locus were resistant to human immunodeficiency virus (HIV) infection, while those heterozygous for the mutation progressed more slowly, led to the discovery of maraviroc (MVC), a CCR5 antagonist. " 03/01/2015 - "Sixty-six patients started a maraviroc-containing cART with a history of HIV infection lasting 13.9±10.7 years. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 12/01/2010 - "The objective of this study was to predict the long-term clinical impact and cost-effectiveness of maraviroc in treatment-experienced adults with HIV/AIDS in Mexico. " 10/15/2007 - "The 48 week interim results of this trial using twice daily maraviroc were reported at the International AIDS Society meeting in July 2007. " 01/01/2014 - "Maraviroc, discovered as a CCR5 antagonist, is the only CCR5 inhibitor that has been approved by both US FDA and the European Medicines Agency (EMA) for treating HIV/AIDS patients. " 01/01/2012 - "However our modelling also indicates that administration of maraviroc as a monotherapy or with BT of suboptimal efficacy can promote emergence of X4 tropic virus, resulting in accelerated progression to AIDS. " 02/01/2009 - "Although one antagonist--maraviroc, a CCR5 inhibitor to treat AIDS--has been registered as an approved drug, this is the only success so far. "
4.	Inflammation 07/01/2015 - "Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. " 01/01/2010 - "Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and inflammation, although in this small study, many of the differences were not statistically significant. " 06/01/2014 - "Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers." 03/01/2013 - "These results support the additional immunological effects of CCR5 blockade and suggest that maraviroc might have potential capacity to inhibit HIV-associated chronic inflammation and activation, both by directly affecting T cell activation and by reducing entrapment of lymphocytes in lymph nodes." 05/28/2013 - "Therefore, maraviroc could benefit HIV-positive patients with residual chronic inflammation who are at a high risk of acute coronary disease despite a suppressive antiretroviral therapy. "
5.	Immune Reconstitution Inflammatory Syndrome 11/01/2014 - "Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial." 01/30/2014 - "Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome." 11/27/2009 - "Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?" 01/01/2014 - "Due to the lack of therapeutic options for patients with progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome (PML-associated IRIS), maraviroc has generated expectations among the medical community. " 03/01/2015 - "High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc."

Related Drugs and Biologics

1.	Carbon Monoxide
2.	CCR5 Receptors (CCR5 Receptor)
3.	Ritonavir (Norvir)
4.	Methotrexate (Mexate)
5.	Tacrolimus (Prograf)
6.	Cytochromes
7.	MK 0518
8.	Lamivudine (3TC)
9.	efavirenz (Sustiva)
10.	Zidovudine (Retrovir)

Related Therapies and Procedures

1.	Oral Administration
2.	Hematopoietic Stem Cell Mobilization
3.	Transplantation (Transplant Recipients)
4.	Polypharmacy
5.	Stents